2004
DOI: 10.1038/sj.pcan.4500752
|View full text |Cite
|
Sign up to set email alerts
|

Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients

Abstract: Introduction: Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with bone lysis by osteoclast proliferation, paralleling nearby bone deposition. The treatment options are palliative and have poor clinical response with short-lived improvement. We have studied the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
19
0
1

Year Published

2006
2006
2024
2024

Publication Types

Select...
3
2
2

Relationship

0
7

Authors

Journals

citations
Cited by 26 publications
(21 citation statements)
references
References 23 publications
1
19
0
1
Order By: Relevance
“…Ernst et al 2003;Heidenreich et al 2005;Hering et al 2003;Rodrigues et al 2004;Saad and Eastham, 2010a;Saad et al 2004;Small et al 2003]. …”
Section: Castration-resistant Prostate Cancerunclassified
See 2 more Smart Citations
“…Ernst et al 2003;Heidenreich et al 2005;Hering et al 2003;Rodrigues et al 2004;Saad and Eastham, 2010a;Saad et al 2004;Small et al 2003]. …”
Section: Castration-resistant Prostate Cancerunclassified
“…It is therefore important to distinguish between BP use to preserve BMD during ADT or palliate pain from PC bone metastases and BP therapy to reduce the risk of SREs in patients with advanced CRPC. Zoledronic acid is the only BP approved for the latter purpose, although several BPs have demonstrated palliative benefits in patients with bone metastases from PC (Table 1) [Donat et al 2006;Ernst et al 2003;Heidenreich et al 2005;Hering et al 2003;Rodrigues et al 2004;Saad and Eastham, 2010a;Saad et al 2004;Small et al 2003]. …”
Section: Castration-resistant Prostate Cancermentioning
confidence: 99%
See 1 more Smart Citation
“…If implants can be used, they loosen due to particle-induced activation of osteoclasts [9] or osteoclasts lead to periprosthetic resorption, which in the worst case results in periprosthetic fracture [10]. The pain in metastatic bone disease seems to be mediated at least in part by osteoclastic action and can be alleviated by treatment with bisphosphonates [11]. Bone metastases use osteoclasts to spread inside bones [12].…”
Section: Biomaterialsmentioning
confidence: 99%
“…Moreover, these substances can act as pain relief agents (Verreuther R, 1993;Rodrigues P, et al, 2004). Bisphosphonates, synthetic analogs of the endogenous pyrophosphate molecule, inhibit osteoclast-mediated bone destruction by a decrease bone resorption in patients receiving ADT and/or with metastatic disease (Smith MR, 2003;Ryan CW, et al, 2006;Lipton A, 2004).…”
Section: Effect Of Bisphosphonates On Preventing or Treating Bone Commentioning
confidence: 99%